BDRL — Blonder Tongue Laboratories Share Price
Last trade - 00:00- $1.37m
- $7.43m
- $18.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.09 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.11% | ||
| Return on Equity | -133.98% | ||
| Operating Margin | -11.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.71 | 19.84 | 16.38 | 15.75 | 18.11 | n/a | n/a | -4.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Blonder Tongue Laboratories, Inc., along with its subsidiary R. L. Drake Holdings, LLC (Drake), is a technology research and development company. The Company delivers a range of products and services to telecommunications, cable and fiber optic service delivery operators, as well as broadcasters and media production companies. Its products are deployed in a list of locations, including lodging/hospitality, multi-dwelling units/apartments, broadcast studios/networks, universities/schools, healthcare/hospitals, fitness centers, government facilities/offices, prisons, airports, sports stadiums/arenas, entertainment venues/casinos, retail stores, and small-medium businesses. The Company’s products are divided into five categories: Encoders and Transcoders, NeXgen Gateway (NXG), Coax Distribution, consumer premise equipment (CPE) and Digital Modulation. Its Encoder/Transcoder Products are used by a system operator for encoding and transcoding of digital video.
Directors
- Steven Shea NEC (62)
- Edward Grauch PRE (55)
- Eric Skolnik CFO (56)
- Ronald Alterio SVP (51)
- Allen Horvath SVP (69)
- Robert Palle DRC (75)
- Anthony Bruno IND (80)
- John Burke IND (58)
- Charles Dietz IND (73)
- Michael Hawkey IND (55)
- Stephen Necessary IND (64)
- Gary Scharmett IND (65)
- James Williams IND (63)
- James Williams IND (89)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- November 17th, 1988
- Public Since
- December 14th, 1995
- No. of Shareholders
- 58
- No. of Employees
- 67
- Sector
- Communications & Networking
- Industry
- Technology
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 14,399,191
- Address
- 1 Jake Brown Rd, OLD BRIDGE, 08857-1000
- Web
- https://www.blondertongue.com/
- Phone
- +1 9086794000
- Auditors
- Marcum LLP
Upcoming Events for BDRL
Similar to BDRL
Ability
Pink Sheets on Nasdaq
ADDvantage Technologies
Pink Sheets on Nasdaq
Satelinx International
Pink Sheets on Nasdaq
Alvarion
Pink Sheets on Nasdaq
ATWEC Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 19:40 UTC, shares in Blonder Tongue Laboratories are trading at $0.08. This share price information is delayed by 15 minutes.
Shares in Blonder Tongue Laboratories last closed at $0.08 and the price had moved by -55.74% over the past 365 days. In terms of relative price strength the Blonder Tongue Laboratories share price has underperformed the S&P500 Index by -62.85% over the past year.
There is no consensus recommendation for this security.
Blonder Tongue Laboratories does not currently pay a dividend.
Blonder Tongue Laboratories does not currently pay a dividend.
Blonder Tongue Laboratories does not currently pay a dividend.
To buy shares in Blonder Tongue Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.08, shares in Blonder Tongue Laboratories had a market capitalisation of $1.17m.
Here are the trading details for Blonder Tongue Laboratories:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BDRL
Based on an overall assessment of its quality, value and momentum Blonder Tongue Laboratories is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Blonder Tongue Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -33.01%.
As of the last closing price of $0.08, shares in Blonder Tongue Laboratories were trading -37.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Blonder Tongue Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Blonder Tongue Laboratories' management team is headed by:
- Steven Shea - NEC
- Edward Grauch - PRE
- Eric Skolnik - CFO
- Ronald Alterio - SVP
- Allen Horvath - SVP
- Robert Palle - DRC
- Anthony Bruno - IND
- John Burke - IND
- Charles Dietz - IND
- Michael Hawkey - IND
- Stephen Necessary - IND
- Gary Scharmett - IND
- James Williams - IND
- James Williams - IND